AgingResearch.NewsJoin free

Solu Therapeutics

CompanyUnited States

Solu Therapeutics develops one asset, in phase 1 (STX-0712 in acute myeloid leukemia). Mostly other acting on CCR2; based in the United States.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • STX-0712

    Depletes disease-driving CCR2-positive malignant monocytes and bone marrow progenitors.

    Phase 1, Other, CCR2, acute myeloid leukemia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies3

Intelligence